• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Gilead Sciences to pay $300 million for nearly half of Tizona, has option to buy the rest...

cafead

Administrator
Staff member
  • cafead   Jul 21, 2020 at 10:32: AM
via Gilead Sciences Inc. GILD, -0.91% announced Tuesday a deal to buy a 49.9% stake in privately held cancer treatment developer Tizona Therapeutics Inc. for $300 million. Gilead also received an option to buy the remainder of Tizona for up to an additional $1.25 billion, including potential future milestone payments.

article source
 

<